An experimental chewing gum containing plant-based compounds has demonstrated a significant ability to reduce levels of human papillomavirus (HPV), a primary cause of various cancers, according to research from the University of Pennsylvania. The study found that the gum reduced HPV levels by more than 90 percent in oral rinse and saliva samples from patients diagnosed with head and neck squamous cell carcinoma.
HPV is a widespread sexually transmitted infection that, while often clearing on its own, can persist in the body for decades and contribute to cancers of the cervix, head and neck, and anus. Despite the availability of HPV vaccines, millions remain unvaccinated, leaving them vulnerable.
The research, published in Scientific Reports, tested two formulations of chewing gum derived from lablab beans. One gum contained a compound targeting HPV particles, while the other targeted bacteria such as Porphyromonas gingivalis and Fusobacterium nucleatum, which have been linked to oral cancer. In tests using samples from 44 head and neck cancer patients, the compounds reduced HPV-16, a high-risk HPV strain, by up to 90 percent. Levels of the targeted bacteria were reduced by over 99 percent after a single treatment.
Researchers noted that the gum's compounds spared beneficial oral bacteria, similar to how more aggressive treatments like radiation can. Unlike radiation, however, this approach did not encourage the growth of other harmful pathogens.
Dr. Henry Daniell, the study's lead author from the University of Pennsylvania's School of Dental Medicine, highlighted the potential of these findings. "Our findings support the value of advancing these therapies to clinical trials as adjuvants with current treatments or as prophylaxis to prevent infection and transmission," Daniell stated. He pointed out that lip and oral cavity cancer was the seventh leading cancer globally in adolescents, young adults, and middle-aged adults in 2022.
HPV is implicated in approximately one in four head and neck cancers and a significant majority of oropharyngeal cancers. It is also responsible for nearly all cervical cancers and many anal, vaginal, vulvar, and penile cancers. In the U.S., the National Cancer Institute reports about 72,000 new head and neck cancer diagnoses and 17,000 deaths annually.
The researchers emphasize that these results stem from testing gum extracts on patient samples, not from patients consuming the gum directly. Further human clinical trials are planned to explore the technology's potential as a low-cost, accessible treatment or preventative measure.